PT2181190E - Enzimas aciltransferase de lecitina-colesterol modificadas - Google Patents

Enzimas aciltransferase de lecitina-colesterol modificadas Download PDF

Info

Publication number
PT2181190E
PT2181190E PT08796592T PT08796592T PT2181190E PT 2181190 E PT2181190 E PT 2181190E PT 08796592 T PT08796592 T PT 08796592T PT 08796592 T PT08796592 T PT 08796592T PT 2181190 E PT2181190 E PT 2181190E
Authority
PT
Portugal
Prior art keywords
cholesterol acyltransferase
modified lecithin
acyltransferase enzymes
enzymes
lecithin
Prior art date
Application number
PT08796592T
Other languages
English (en)
Inventor
Mingyue Zhou
Thomas Boone
David Park Meininger
Margrit Schwartz
Bei Shan
Wenyan Shen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT2181190E publication Critical patent/PT2181190E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
PT08796592T 2007-07-26 2008-07-25 Enzimas aciltransferase de lecitina-colesterol modificadas PT2181190E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95200707P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
PT2181190E true PT2181190E (pt) 2014-02-24

Family

ID=39864722

Family Applications (2)

Application Number Title Priority Date Filing Date
PT08796592T PT2181190E (pt) 2007-07-26 2008-07-25 Enzimas aciltransferase de lecitina-colesterol modificadas
PT12003811T PT2489731E (pt) 2007-07-26 2008-07-25 Enzimas aciltransferase de lecitina-colesterol modificadas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT12003811T PT2489731E (pt) 2007-07-26 2008-07-25 Enzimas aciltransferase de lecitina-colesterol modificadas

Country Status (26)

Country Link
US (3) US8168416B2 (pt)
EP (4) EP2489731B1 (pt)
JP (5) JP5643643B2 (pt)
KR (1) KR20100040937A (pt)
CN (1) CN101855344B (pt)
AU (1) AU2008279065B2 (pt)
BR (1) BRPI0814310A2 (pt)
CA (1) CA2694590A1 (pt)
CR (1) CR11272A (pt)
CY (2) CY1114857T1 (pt)
DK (2) DK2181190T3 (pt)
EA (1) EA201070187A1 (pt)
ES (3) ES2449483T3 (pt)
HK (1) HK1138039A1 (pt)
HR (1) HRP20140315T1 (pt)
IL (1) IL203399A0 (pt)
MX (1) MX348799B (pt)
MY (1) MY159075A (pt)
NZ (2) NZ597885A (pt)
PL (2) PL2181190T3 (pt)
PT (2) PT2181190E (pt)
RS (1) RS53237B (pt)
SG (1) SG186016A1 (pt)
SI (2) SI2181190T1 (pt)
UA (1) UA103304C2 (pt)
WO (1) WO2009015314A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5643643B2 (ja) * 2007-07-26 2014-12-17 アムジエン・インコーポレーテツド 変性レシチン−コレステロールアシルトランスフェラーゼ酵素
ES2552654T3 (es) 2009-06-12 2015-12-01 Medimmune, Llc Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
RU2012152320A (ru) * 2010-05-06 2014-06-20 АЛЬФАКОР ФАРМА ЭлЭлСи Доставка эфиров холестерина в стероидогенные ткани
WO2012114131A1 (en) * 2011-02-25 2012-08-30 University Of Patras Lecithin:cholesterol acyltransferase (lcat) and its role in nonalcoholic fatty liver disease (nafld)
BR112013028271B1 (pt) 2011-05-05 2020-11-24 Wellstat Immuno Therapeutics, Llc Polipeptideo, acido nucleico, vetor viral, preparação farmaceutica, bem como uso dos mesmos no tratamento de doenqa mediada por complemento
CN104220460A (zh) 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
US10583104B2 (en) * 2014-08-06 2020-03-10 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
US20180265885A1 (en) * 2015-01-29 2018-09-20 Plantvax, Inc. Highly expressed protective plant-derived broadly neutralizing hiv monoclonal antibodies for use in passive immunotherapy
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
CN111601614A (zh) * 2017-11-07 2020-08-28 阿尔法科制药有限责任公司 治疗和预防心脏病、心血管疾病及相关病症和症状的方法
BR112020023394A2 (pt) * 2018-05-22 2021-02-09 Dsm Ip Assets B.V. esterol aciltransferases modificadas
US11612619B2 (en) 2018-11-01 2023-03-28 National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Compostions and methods for enabling cholesterol catabolism in human cells
KR200493485Y1 (ko) * 2019-08-27 2021-04-07 주식회사 서원기술 배관용 고무링

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS63167409A (ja) 1986-12-27 1988-07-11 Yamaha Corp 磁気記録体
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
EP0306228B1 (en) 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
ATE106249T1 (de) 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
DK0680320T3 (da) 1993-01-19 1999-10-25 Warner Lambert Co Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1997003959A1 (en) 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
DE69636907T2 (de) * 1995-11-09 2007-11-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
AU6748198A (en) * 1997-04-11 1998-11-11 Takeda Chemical Industries Ltd. Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
DE69818444T2 (de) 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001005943A2 (en) 1999-07-14 2001-01-25 Betagene, Inc. Lcat recombinant cell line compositions and methods
ATE540681T1 (de) * 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
JP5643643B2 (ja) * 2007-07-26 2014-12-17 アムジエン・インコーポレーテツド 変性レシチン−コレステロールアシルトランスフェラーゼ酵素

Also Published As

Publication number Publication date
IL203399A0 (en) 2011-07-31
EP2489730B1 (en) 2015-12-30
JP2016182136A (ja) 2016-10-20
CN101855344B (zh) 2015-12-09
SI2181190T1 (sl) 2014-04-30
SI2489731T1 (sl) 2014-12-31
CY1114857T1 (el) 2016-12-14
EP2522721A3 (en) 2013-01-23
HRP20140315T1 (hr) 2014-05-09
US20140287479A1 (en) 2014-09-25
MY159075A (en) 2016-12-15
WO2009015314A3 (en) 2009-03-12
PL2181190T3 (pl) 2014-06-30
CN101855344A (zh) 2010-10-06
AU2008279065B2 (en) 2013-12-12
EP2522721B1 (en) 2016-05-04
HK1138039A1 (en) 2010-08-13
US8703926B1 (en) 2014-04-22
EP2522721A2 (en) 2012-11-14
CA2694590A1 (en) 2009-01-29
EP2489730A1 (en) 2012-08-22
EP2181190B1 (en) 2014-01-08
ES2513716T3 (es) 2014-10-27
MX348799B (es) 2017-06-29
US9006408B2 (en) 2015-04-14
CY1115573T1 (el) 2017-01-04
EA201070187A1 (ru) 2010-08-30
JP2010534479A (ja) 2010-11-11
EP2181190A2 (en) 2010-05-05
PT2489731E (pt) 2014-09-15
JP5643643B2 (ja) 2014-12-17
UA103304C2 (ru) 2013-10-10
ES2559353T3 (es) 2016-02-11
PL2489731T3 (pl) 2015-01-30
JP2018161134A (ja) 2018-10-18
JP2014198047A (ja) 2014-10-23
NZ597885A (en) 2013-08-30
DK2489731T3 (en) 2014-11-17
BRPI0814310A2 (pt) 2015-01-06
DK2181190T3 (da) 2014-03-31
NZ582794A (en) 2012-09-28
ES2449483T3 (es) 2014-03-19
US8168416B2 (en) 2012-05-01
JP6033258B2 (ja) 2016-11-30
RS53237B (en) 2014-08-29
WO2009015314A2 (en) 2009-01-29
US20090081182A1 (en) 2009-03-26
EP2489731B1 (en) 2014-08-27
SG186016A1 (en) 2012-12-28
KR20100040937A (ko) 2010-04-21
EP2489731A1 (en) 2012-08-22
JP2020058366A (ja) 2020-04-16
AU2008279065A1 (en) 2009-01-29
CR11272A (es) 2010-05-26

Similar Documents

Publication Publication Date Title
HK1138039A1 (en) Modified lecithin-cholesterol acyltransferase enzymes
HK1148519A1 (en) Diacylglycerol acyltransferase inhibitors
GB0719620D0 (en) Mutant Enzymes
HUE036318T2 (hu) Módosított foszfatázok
EP2169055A4 (en) NEW LYSOPHOSPHATIDATE ACYLTRANSFERASE GENE
PL2017352T3 (pl) Sensor elektrochemiczny z kowalencyjnie związanym enzymem
EP2119781A4 (en) Glyceroglycolipid LIPASE
EP2467477A4 (en) FAST-ACTING SNARE-COLUMN ENZYMES
EP2192402A4 (en) ENZYME ELECTRODE
GB0804721D0 (en) Enzyme
GB0818328D0 (en) Novel enzyme
ZA201107395B (en) Enzyme with silaffin
GB0803628D0 (en) Enzyme
EP1997896A4 (en) GENEIGNING AND LIGNAN METHYLATING ENZYME
GB0804722D0 (en) Enzyme
IL207848A0 (en) Artificial enzymes
GB0800831D0 (en) Enzymes 1
GB0617387D0 (en) Synthetic gene
HU0600159D0 (en) Kvantitative pcr
GB0716735D0 (en) Insert stove
GB2467284B (en) Sulfatase enzymes
GB0711245D0 (en) Enzyme
GB0713609D0 (en) Enzyme
GB0711246D0 (en) Enzyme
GB0713610D0 (en) Enzyme